|Bid||0.00 x 1000|
|Ask||0.00 x 1300|
|Day's Range||56.22 - 58.74|
|52 Week Range||21.75 - 111.36|
|PE Ratio (TTM)||10.87|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||89.38|
This analysis is intended to introduce important early concepts to people who are starting to invest and want to begin learning the link between company’s fundamentals and stock market performance.Read More...
In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017. In the first half of the year, Spectrum Pharmaceuticals reported net revenues of $54.7 million compared to $63.4 million in H1 2017.
On September 6, Spectrum Pharmaceuticals stock closed at $22.25, which is a ~5.70% rise from its close of $21.05 on September 5, 2018. On September 6, Spectrum Pharmaceuticals stock price closed at $22.25, which represents ~146% growth from its 52-week low of $9.03 on September 22, 2017. Spectrum Pharmaceuticals hit its 52-week high of $25.29 on August 27, 2018.
NEW YORK, NY / ACCESSWIRE / September 5, 2018 / Wall Street finished in the red on Tuesday as investors focused on the latest trade negotiations between the U.S. and Canada, potentially paving the way ...
NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Caesars ...
Biotech stocks have put together a solid year as measured by the iShares Nasdaq Biotechnology ETF ( IBB). Shares of Alkermes PLC ( ALKS), BeiGene Ltd. ( BGNE) and Nektar Therapeutics Inc. ( NKTR ), are three stocks in the ETF that could help to lead the way higher for the rest of the sector over the coming months. BeiGene is nearly 21% off its 2018 highs of nearly $220, but shares have found a strong level of technical support at roughly $154.
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
In July, Nektar Therapeutics’ (NKTR) new drug application for NKTR-181 was accepted for filing by the FDA. A first-in-class analgesic, NKTR-181 is targeted at the treatment of chronic low back pain in adult patients who are new to opioid therapy.
How Is Nektar Therapeutics Positioned in August? In February, Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) entered into a collaboration to jointly develop the former’s NKTR-214 in combination with the latter’s Opdivo and Opdivo plus Yervoy and other compounds. The two companies also agreed that Nektar would retain the right to record all global sales of the drug.
How Is Nektar Therapeutics Positioned in August? Nektar Therapeutics expects an increase in its general and administrative expenses in 2018 compared to 2017 due to higher noncash stock-based compensation expenses. Nektar Therapeutics saw an operating income of -$50.66 million in the second quarter of 2017 compared to its operating income of $973.6 million in the second quarter of 2018.
Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.
Nektar Therapeutics (NKTR) generated revenue of $1.09 billion in the second quarter compared to $34.59 million in the second quarter of 2017.
As the following stock charts of Nektar Therapeutics (NASDAQ:NKTR), Waters (NYSE:WAT) and A.O. Smith (NYSE:AOS) indicate, some stocks are still well-positioned to move higher. Nektar Therapeutics, though, is an exception to that rule of thumb. • A careful look at the daily chart also makes clear that Nektar Therapeutics shares found support at key short-term moving average lines, which is where you’d expect/want to find support.
Nektar's (NKTR) second-quarter earnings meet estimates. Although revenues soar on one-time payment from Bristol-Myers, product sales fall. Shares down.
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / U.S. equities were mixed on Wednesday as a result of disappointing corporate earnings combined with the latest trade news. The Dow Jones Industrial Average ...
Nektar Therapeutics (nktr) shares swung lower in the extended session Wednesday after the biotech company reported quarterly earnings. Nektar shares, which had been up as much as 5% after hours, were last trading down 4.6% in the extended session, following a 2.5% gain to close the regular session at $55.96.
Nektar (NKTR) delivered earnings and revenue surprises of 0.00% and 4.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?